Advice for Community Oncologists on Optimizing Frontline BTKi for CLL

Daniel Ermann, MD, shares his expert insight on proactive management of patients with chronic lymphocytic leukemia receiving BTK inhibitor (BTKi) therapy to ensure optimal treatment, particularly in older patients. He says that BTKi therapy is “generally very well tolerated.” Ermann stresses the importance of counseling and monitoring older patients starting BTKi, particularly regarding their baseline cardiac comorbidity profile, as well as infection and bleeding risks.